Pharmala Biotech Holdings Inc

Canadian Securities Exchange:MDMACanadaView on Grey Market

PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.

Contact Information

Headquarters

82 Richmond St. EastVANCOUVER, BC, Canada M5C 1P1

Phone

---

Fax

---

Executives

Independent Chairperson of the Board

Jodi Butts

President, Chief Executive Officer, Director

Nicholas Kadysh

Chief Financial Officer, Corporate Secretary

Carmelo Marrelli

Chief Operating Officer

Shane Morris

Independent Director

Harriet De Wit